- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SmartLight slashes prices
Digital light box developer SmartLight has reduced the price of its products by up to 40%, thanks to a significant decrease in the firm’s production costs, according to the Hackensack, NJ-based company. As a result, SmartLight’s entry-level SL
Digital light box developer SmartLight has reduced the price of its products by up to 40%, thanks to a significant decrease in the firms production costs, according to the Hackensack, NJ-based company. As a result, SmartLights entry-level SL 2000Plus product now costs approximately $10,000, while the Smart Motorized Viewer starts as low as $49,000.
In other developments, SmartLight has reported an increase in sales volume, owing to its direct sales efforts and distribution deals with Fuji Medical in Japan and Siemens Medical Systems in Germany (SCAN 6/24/98 and 4/14/99). The company has also opened an expanded manufacturing facility in Yokheam, Israel.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
